During a surgical or endoscopic operation on a body lumen, e.g., a blood vessel, an aperture is formed (e.g., from an arteriotomy) in the tissue of the lumen. Following the procedure, the aperture has to be closed in order for the lumen to heal. One relatively new type of closure apparatus has a flexible disc that is delivered into the body lumen to seal the aperture. The disc maintains the tissue in apposition until the lumen is healed, allowing the wound to heal from the inside of the lumen. The disc may operate in conjunction with a rigid core, which prevents the disc from dislodging from the sealing position.
In certain patient groups, the area surrounding the tissue within the body lumen is diseased and/or has accumulation (e.g., plaque or calcified lesions on the tissue wall). Due to the irregular surface topology of such areas, the effectiveness of the seal made by certain closure apparatuses is reduced, as channels are formed between the disc and the tissue surface.
There are benefits of improving the seal formed by a closure apparatus when closing an aperture formed in the tissue of the body lumen.
During a surgical or endoscopic or other minimally invasive operation on a body lumen, e.g., a blood vessel, an aperture is formed (e.g., from an arteriotomy or a veinotomy) in the tissue of the lumen. Closure and healing can be assisted by a closure apparatus, e.g., an apparatus that has a flexible disc that is delivered into the body lumen to seal the aperture, and/or a rigid core, which prevents the disc from dislodging from the sealing position. The disclosed technologies can improve the seal formed by a closure apparatus when closing an aperture formed in the tissue of the body lumen. In certain embodiments, the disclosed technologies assist the closure of an aperture, e.g., by providing a compressive force on the exterior surface of a vessel, e.g., using an extra-arterial cage or shoe.
In one aspect, the invention is directed to a device for fixating an implant, the device comprising a shoe comprising one or more engagement elements for engagement with a column or support member of the implant. In certain embodiments, the shoe has a caged structure. In certain embodiments, the shoe comprises one or more concave structural elements. In certain embodiments, at least one structural element of the shoe is selected from the group consisting of indentations, ridges, shoulders, planes, curved planes, cavities, notches, holes, slots surfaces, and grooves. In certain embodiments, the device comprises at least one hole and one shoulder. In certain embodiments, the device is bioabsorbable. In certain embodiments, the device comprises at least one material selected from the group consisting of Polydioxanone, Poly-L-lactide, Poly-D-lactide, Poly-DL-lactide, Polyglycolide, ε-Caprolactone, and Polyethylene glycol. In some embodiments, the material of the support member and/or sealable member is a co-polymer of, for example, but not limited to, Polydioxanone, Poly-L-lactide, Poly-D-lactide, Poly-DL-lactide, Polyglycolide, ε-Caprolactone, and Polyethylene glycol.
In another aspect, the invention is directed to a device for sealing an aperture in a tissue of a body lumen, the device comprising: (i) a flexible support member comprising a base and a sealable member; (ii) a column comprising a centering tab and/or one or more locking tabs; and (iii) an extra-arterial shoe comprising one or more engagement elements for engagement with the flexible support member. In certain embodiments, the extra-arterial shoe comprises a shoulder. In certain embodiments, the one or more locking tabs engage with the extra-arterial shoe by snap fitting with the shoe. In certain embodiments, the one or more locking tabs engage with the extra-arterial shoe by engaging the shoulder of the shoe. In certain embodiments, the column comprises two locking tabs. In certain embodiments, the locking tabs are positioned opposite to each other along the circumference of a cylindrical portion of the flexible support member. In certain embodiments, the centering tab reversibly engages one or more features of the extra-arterial shoe. In certain embodiments, the one or more features are a notch, a hole, surface, or a groove. In certain embodiments, the device comprises a delivery system comprising an external shaft. In certain embodiments, the extra-arterial shoe is mounted on the external shaft and is slideably moveable along a longitudinal axis of the external shaft. In certain embodiments, the device comprises a shoe pusher. In certain embodiments, the shoe pusher is mounted on the external shaft and is slideably moveable along a longitudinal axis of the external shaft.
In another aspect, the invention is directed to a device for sealing an aperture in a tissue of a body lumen, the device comprising: (i) a flexible support member comprising a base and a sealable member; (ii) a column comprising a centering tab and/or one or more locking tabs; (iii) an extra-arterial shoe comprising one or more engagement elements for engagement with the flexible support member; (iv) a delivery system comprising an external shaft having a longitudinal axis; and (v) a shoe pusher. In certain embodiments, the extra-arterial shoe is mounted on the external shaft and is slideably moveable along a longitudinal axis of the external shaft, and the shoe pusher is mounted on the external shaft and is slideably moveable along a longitudinal axis of the external shaft. In certain embodiments, the shoe pusher is reversibly engageable to the external shoe. In certain embodiments, the shoe pusher and the extra-arterial shoe are moveable between a first, proximal position and a second, distal position, such that in the first position, the shoe pusher and the extra-arterial shoe are reversibly engaged and slideably moveable along the longitudinal axis, and such that in the second position, the extra-arterial shoe engages the flexible support member. In certain embodiments, the shoe pusher is moveable to a third, proximal position. In certain embodiments, the extra-arterial shoe, upon deployment and engagement, is capable of exerting pressure on an exterior surface of the tissue. In certain embodiments, the aperture in a tissue of a body lumen is a surgical or endoscopic perforation in a body cavity.
In another aspect, the invention is directed to a device for sealing an aperture in a tissue of a body lumen, the device comprising: (i) a flexible support member comprising a base and a sealable member; (ii) a column comprising a locking neck; and (iii) an extra-arterial shoe comprising one or more engagement elements for engagement with the flexible support member. In certain embodiments, the extra-arterial shoe comprises an engagement slot. In certain embodiments, the locking neck engages with the extra-arterial shoe by snap fitting with the shoe. In certain embodiments, the locking neck engages with the extra-arterial shoe by engaging the engagement slot. In certain embodiments, the device comprises a delivery system comprising an external shaft. In certain embodiments, the extra-arterial shoe is mounted on the external shaft and is slideably moveable along a longitudinal axis of the external shaft. In certain embodiments, the device comprises a shoe pusher. In certain embodiments, the shoe pusher is mounted on the external shaft and is slideably moveable along a longitudinal axis of the external shaft.
In certain embodiments, the body lumen is the inside space of a biological structure selected from the group consisting of gastrointestinal tract, heart, peritoneal cavity, esophagus, vagina, rectum, trachea, bronchi, and blood vessel, e.g., the femoral artery, iliac artery, subclavian artery, ascending and descending aorta, auxiliary and brachial arteries, femoral vein, iliac vein, subclavian vein, and vena cava.
Further features and aspects of example embodiments of the present invention are described in more detail below with reference to the appended Figures.
As described herein, illustrative embodiments provide surgical closure systems, devices, and methods useful for (i) bringing about alignment of the tissues surrounding a perforation in a body lumen, thereby closing the aperture in the body lumen, (ii) forming a tamponade at the aperture when bringing about the alignment of the tissues, and (iii) maintaining the tissues surrounding the perforation in alignment until the perforation is sealed. The systems, devices, and methods are used, in some embodiments, to close a surgical perforation in a body cavity, such as the gastrointestinal tract, heart, peritoneal cavity, esophagus, vagina, rectum, trachea, bronchi, and blood vessel, including for example, but not limited to the femoral artery, subclavian artery, ascending and descending aorta, auxiliary and brachial arteries femoral vein, iliac vein, subclavian vein, and vena cava.
The closure device 100 includes a sealable member 106 (e.g., a flexible wing) positionable against an interior surface 108 of the tissue 110 adjacent the aperture 112 in the tissue (e.g., so as to form a tamponade at the aperture 112). Although flat or slightly curved when in a relaxed state, the sealable member 106 flexibly curves to conform to the interior surface 108 of the lumen 104 to which it engages, in the deployed state.
The closure device 100 includes a support member 118 (e.g., a foot) comprising a base 120 (e.g., an O-ring foot-core) and a column 122. The base 120 supports the sealable member 106 during the delivery and deployment of the sealable member 106 in the body lumen 104 by retaining and/or holding the sealable member 106 against the interior surface 108 of the tissue 110 when the closure device 100 is in the sealing position. In some embodiments, the base 120 exerts a force to bias the sealable member 106 against the tissue.
In some embodiments, once implanted in the body lumen, the base 120 presses against the interior shape of the lumen 104 by hydraulic pressure exerted by fluids in the body lumen 104 (e.g., by hemodynamic hydraulic forces exerted by blood in a blood vessel). In doing so, the base 120 improves the seal formed by the sealable member 106 over the aperture 112, thus, providing a faster and more secure closure of the aperture 112. The base 120 connects to the column 122, which is disposed, when the device is in the sealing position, in and through the aperture 110. In certain embodiments, a guard member 126 (see
In some embodiments, once implanted in the body lumen, the base 120 bends against the interior shape of the lumen 104 so as to compress the peripheral portions of the sealable member 106 against the interior surface 108 of the tissue 110. Hydraulic pressure, as discussed above, may contribute to the bending of the base 120 in such embodiments. The base 120, in these embodiments, also improves the seal formed by the sealable member 106 over the aperture 112, thus, providing a faster and more secure closure of the aperture 112. The support member 118 may also include a guard member 126 to prevent the dislodgement of the sealable member 106 from the sealing position, e.g., due to impact near the aperture or movement of the patient.
In some embodiments, the support member 118 may include a guard member 126 to prevent the dislodgement of the sealable member 106 from the sealing position, when hydraulic pressure of a blood vessel is relatively low. The guard member may provide a mean to compress the implant into a vessel (e.g., by an operator).
Lateral Support Portions of the Base
In some embodiments, the central portion 302 forms a rigid core to which the lateral support portions 306 flexibly connect. In some embodiments, the central portion 302 and the lateral support portions 306 form a single unitary body.
In some embodiments, the lateral support portions 306 forms a gap 320 with respect to the central portion 302.
Still referring to
Directionally-Inducted Rigidity of the Devices
In another aspect, the flexible support member 118 may be shaped to provide more rigidity to peripheral portions of the sealable member 106 along a direction to which the sealable member is pulled during the deployment of the closure device 100. The directionally-induced rigidity ameliorates the risk of an accidental pull-out of the sealable member from the lumen 104 during deployment.
As shown in
In certain embodiments, the base 120 of the support member 118 has a varying cross-sectional thickness along the direction between the anterior support portion 310 and the posterior support portion 312. The varying thickness along this direction may provide greater rigidity at the posterior support portion 312 of the base 120 than the anterior support portion 310.
Referring still to
In addition, the lateral support portions 306 may extend from the anterior support portion 310 at a location 414 between an anterior end 416 of the anterior support portion 310 and the central portion 302, thereby forming a region 418. This region 418 can also be characterized as a tab 418. The tab 418 provides additional surface area 420 to the anterior region of the sealable member 106.
In some embodiments, as shown in
In some embodiments, as shown in
As shown, the column 122 of the support member 118 is angularly disposed, when secured to the apparatus 500, along an axis 502 corresponding to a longitudinal axis of a delivery shaft 504 to which the closure device 100 is releasably attached. The delivery shaft 504 may engage the column 122, in some embodiments, at two recesses 510 located on the proximal tip of the column 122. In certain embodiments, the column 122 forms an angle 506 between a plane 508 corresponding to the sealable member 106 in a rest configuration and the longitudinal axis 502 of the delivery shaft 504. In certain embodiments, the angle 506 is between about 10 degrees and about 70 degrees, including, but not limited to, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, and 70 degrees.
Additional examples of the delivery apparatus is found in U.S. Patent Application Publication No. US 2014/0018846, titled “Implants and Methods for Percutaneous Perforation Closure,” the content of which is incorporated herein in its entirety.
Examples of the Support Member
Various embodiments of the lateral support portions are now described. In some embodiments, the lateral support portions 306 extend from the central portion 302 to form a continuous structure, for example, but not limited to, a ring (e.g., circle, oval, rectangular, ellipse, diamond) around the central portion 302 of the base 120. In other embodiments, the lateral support portions 306 form one or more cantilevers that extend from the central portion 302.
As shown in
As shown in
As shown in
As shown in
As shown in
In
Referring still to
In
In
In
Additional views of the various embodiments, as well as further examples of the closure device 100, are provided in
Other Components of the Closure Device
Referring back to
Examples of the extra-luminal pin are described U.S. Patent Application Publication No. US 2014/0018847, titled “Percutaneous Perforation Closure Systems, Devices, and Methods.” In other embodiments, the engagement portion 124 is a protrusion or a recess on the exterior surface of the column 122 to which a slotted cage or shoe (as a guard member) can engage.
In certain embodiments, the base 120 of the support member 118 has a uniform thickness between about 0.1 mm and about 1.5 mm, including 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1.0, 1.05, 1.10, 1.15, 1.20, 1.25, 1.30, 1.35, 1.40, 1.45, and 1.5 mm. In other embodiments, the thickness is varying.
The sealable member 106, in some embodiments, is sized to be larger than the diameter of the aperture (e.g., between 12 F and 30 F). In some embodiments, the sealable member 106 has a thickness preferably between about 0.05 mm and about 0.6 mm. In some embodiments, the sealable member 106 has a thickness between about 0.005 mm and 4 mm, e.g., depending on the size of the aperture and the size of the vessel/lumen.
In certain embodiments, the thickness of the sealable member and/or support member, as deployed in the vessel/lumen, is selected based on the size of the aperture to be sealed and/or the size of the blood vessel/hollow vessel. Table 1 lists exemplary ranges of thicknesses of a sealable member to close an aperture based on the aperture/incision size that is formed. Table 2 lists exemplary ranges of thicknesses of the sealable member to close an aperture based on the vessel diameter size. Table 3 lists exemplary ranges of thicknesses of sealable member to close an aperture base on the size of the hollow vessel.
The sealable member 106 is preferably circular in shape. It should be understood, however, that other geometries may be provided for the hole and/or the disk portion, including, but not limited to, ovals. The sealable member 106 has a hole (e.g., located at or near the center of the member) sized to accept the column 122. In some embodiments, the sealable member 106 is free to rotate relative to the base 120 of the support member 118 about an axis concentric to the column 122. Other examples of the sealable member is described in U.S. Patent Application Publication No. US 2014/0018847, titled “Percutaneous Perforation Closure Systems, Devices, and Methods,” and U.S. Provisional Application No. 62/092,212, titled “Implantable Sealable Member with Mesh Layer,” the content of each of these applications is incorporated by reference herein in its entirety.
The sealable member and/or the base comprises, in some embodiments, at least one material selected from the group consisting of Polydioxanone, Poly-L-lactide, Poly-D-lactide, Poly-DL-lactide, Polyglycolide, ε-Caprolactone, Polyethylene glycol, and a copolymer thereof. In some embodiments, the material of the sealable member and/or the base is a copolymer of Polydioxanone, Poly-L-lactide, Poly-D-lactide, Poly-DL-lactide, Polyglycolide, ε-Caprolactone, and Polyethylene glycol. In some embodiments, the copolymer includes (a) monomers of Polydioxanone, Poly-L-lactide, Poly-D-lactide, Poly-DL-lactide, Polyglycolide, ε-Caprolactone, or Polyethylene glycol, and (b) one or more additional monomers. In some embodiments, the (a) and (b) monomers form a polymer that is bioabsorbable. One of ordinary skill in the art will appreciate that other suitable biodegradable material may be employed.
In certain embodiments, the thickness of the support member 118 and the sealable member 106 are selected such that the members 106, 118 are bendable to be loaded into the cannula 2202 while having sufficient rigidity to form and maintain a tamponade at the aperture when the device 100 is in the sealing position. In some embodiments, the thickness of the support member 118 and the sealable member 106 are selected such that a portion of the the members 106, 118 is rigid.
In some embodiments, the base 120 of the support member 118 is sufficiently flexible to roll into a delivery funnel used for delivering the implant into the body lumen.
In some embodiments, during deployment to close a hole, e.g., in a hollow vessel, the implant 100 is loaded into a delivery cannula 2102 through a loading funnel 2102 which reduces the cross-sectional area of the implant 100 (e.g., support member 118 and sealable member 106) to make it possible to deliver the implant through an introducer catheter into a hollow vessel (such as an artery or a vein) within which there had been made an access hole to perform a minimally invasive procedure. During this delivery and deployment of the implant, the support member 118 (e.g., O-ring foot core) supports the wing.
As shown in
Referring back to
Threaded Portion on the Support Member
The threaded portion may be employed with a support member having a rigid foot core. Further examples of rigid foot cores are described in U.S. Patent Application Publication No. US 2013/0274795, titled “Devices and Methods for Delivering Implants for Percutaneous Perforation Closure,” the contents of which is incorporated herein in its entirety. Examples of rigid foot core with threaded portions are provided in
In some embodiments, the threaded portion is employed in conjunction with a “button” foot core design. The button foot core, in some embodiments, is round. The profile of the “button” foot core is such that the base diameter is only slightly wider than the hole in the center of the wing. The wing can, thus, be threaded onto the column of the button foot core. An example of the “button” foot core design is provided in
In some embodiments, the “button” foot core design is employed for smaller sized apertures (e.g., between 6 and 18 (F) French), e.g., for usage in smaller-sized blood vessels/lumens.
The sealable member 106 comprises a hole 2004 that has a profile so as to translate along the axis 2002 without contacting the column 122 of the sealable member 118. Alternatively, the sealable member 106 is oriented along a plane parallel to the base 120 during assembly of the sealable member 106 and the support member 118 (not shown).
In certain embodiments, during the assembly, the support member 118 is stationary with respect to the sealable member 106, while the sealable member 106 is moved along the column 122 to the treaded section 1900. In other embodiments, the sealable member 106 is stationary with respect of the support member 118, while the support member 118 is moved through the hole 2004 of the sealable member 106. In yet other embodiments, both the sealable member 106 and the support member 118 move with respect to each other.
Slotted Shoe
In certain embodiments, the surgical closure systems, devices, and methods described herein comprise a device that can exert pressure on the external surface of a tissue. In certain embodiments, the surgical closure systems, devices, and methods described herein comprise an external, e.g., extra-arterial, securing component (e.g., a cage or “shoe”), e.g., to secure a vascular closure device (VCD) implant to a blood vessel and/or to help maintain the seal, e.g., of the arteriotomy or veinotomy by compressing a wall of the artery or vein between it and the wing of the VCD when the device is deployed. In certain embodiments, the cage or shoe, in combination with pressure present in a vessel, e.g., hydraulic pressure present in an artery or vein (e.g., hemodynamic pressure of blood), or other body lumen, improves tamponade formed by the device over the aperture, e.g., an arteriotomy or veinotomy. In some embodiments, the cage or shoe comprises one or more structural features, e.g., indentations, ridges, shoulders, planes, curved planes, cavities, notches, holes, slots, surfaces, and/or grooves. In certain embodiments, the cage or shoe comprises one or more engagement elements (e.g., indentations, ridges, shoulders, planes, curved planes, cavities, notches, holes, slots, surfaces, and/or grooves), e.g., elements that can engage with another device or element, e.g. a support member. In some embodiments, the cage or shoe can be used in combination with column 122 of the support member 118 (see
In certain specific embodiments, the cage or shoe is a shoe 7301 as shown in
In certain embodiments, a support member, e.g., support member 118, comprises tabs, e.g., as shown in
The extra-arterial securing component (e.g., a cage or “shoe”) can be deployed using a variety of methods.
In certain embodiments, the shoe (e.g., shoe 7301) can be moved by a shoe delivery element, e.g., a shoe pusher (e.g., shoe pusher 7702) and/or a delivery shaft, along the longitudinal axis of the external shaft 7703 and/or along the axis 502. In certain embodiments, the shoe pusher is mounted on an external shaft, e.g., external shaft 7703, of the delivery system. In certain embodiments, the shoe pusher is slideably moveable along the longitudinal axis of the external shaft and/or along the axis 502 corresponding to a longitudinal axis of a delivery shaft, e.g., delivery shaft 504. In certain embodiments, deploying the shoe comprises the steps of reversibly engaging the shoe pusher with the shoe and advancing the shoe pusher distally (e.g., toward the implant), e.g., advancing the shoe pusher a set distance. In certain embodiments, the shoe pusher is reversibly engaged with the shoe such that the shoe can only be moved distally (e.g., toward the implant and away from the operator). In certain embodiments, the shoe pusher is engaged with the shoe such that the shoe can be moved distally and/or proximally (e.g., away from the implant and toward from the operator).
In certain embodiments, deploying the shoe comprises the steps of reversibly engaging the shoe pusher with the shoe and advancing the shoe pusher distally (e.g., toward the implant), e.g., advancing the shoe pusher a set distance, and engaging the shoe with the implant (e.g., with the tabbed support member 7401) by locking the shoe onto the locking tabs, e.g., locking tabs 7402, e.g., as shown in
In some embodiments, the cage or shoe comprises one or more shoe connector elements (e.g., shoe connector profiles) and/or delivery shaft profiles. In some embodiments, one or more shoe connector profiles and/or delivery shaft profiles can engage a delivery element, e.g., a shoe pusher and/or a delivery shaft. In some embodiments, one or more shoe connector profiles and/or delivery shaft profiles can engage the implant, e.g., are equivalent to, are part of, comprise, or are identical to the engagement elements engaging the implant, as described above.
In certain specific embodiments, the cage or shoe is a shoe 8101, e.g., as shown in
Without wishing to be bound by theory, the shoe connector and the shoe are designed such that the shoe connector can engage the shoe, e.g., at a shoe connector profile, in order to control the alignment of the shoe relative to the support member, e.g., by preventing the shoe from rotating around the longitudinal axis of column 122. In certain embodiments, the shoe connector profile can have the shape of a circle, square, rectangular, triangle, rhombus and/or any combination or composition thereof. In certain embodiments, the shoe connector profile can have the shape of a key hole.
In certain embodiments, the shoe (e.g., shoe 8101) is deployed by advancing the shoe connector (e.g., shoe connector 8202) distally (e.g., toward the implant), e.g., to a set distance, and engaging the shoe with the implant (e.g., with the tabbed support member 7401) by locking the shoe onto the locking tabs, e.g., locking tabs 7402, e.g., as shown in
In some embodiments, the cage or shoe engages with the implant by engaging a locking neck, e.g., on column 122.
In one exemplary embodiment shown in
In one exemplary embodiment shown in
In some embodiments, the extra-arterial securing component (e.g., a cage or “shoe”) comprises at least one material selected from the group consisting of Polydioxanone, Poly-L-lactide, Poly-D-lactide, Poly-DL-lactide, Polyglycolide, ε-Caprolactone, and Polyethylene glycol. In some embodiments, the material of the support member and/or sealable member is a co-polymer of, for example, but not limited to, Polydioxanone, Poly-L-lactide, Poly-D-lactide, Poly-DL-lactide, Polyglycolide, ε-Caprolactone, and Polyethylene glycol. In some embodiments, the co-polymer includes (a) monomers of Polydioxanone, Poly-L-lactide, Poly-D-lactide, Poly-DL-lactide, Polyglycolide, ε-Caprolactone, or Polyethylene glycol, and (b) one or more additional monomers. In some embodiments, the (a) and (b) monomers form a polymer that is bioabsorbable.
Although the present invention relating to extra-arterial securing component (e.g., a cage or “shoe”) has been described with reference to particular examples and exemplary embodiments, it should be understood that the foregoing description is in no manner limiting. Moreover, the features described herein may be used in any combination.
In some embodiments, the disclosed technology is an implant capable of closing holes in hollow vessels. The implant consists of three distinct parts: a flexible sealing member (e.g., wing), a pin, and a rigid support member (e.g., foot core). This implant may be attached to and packaged with a delivery system. A design is now described below, though other variants, as described herein, may be employed as viable designs to accomplish the same outcomes.
In an example embodiment, the foot core is designed to support the wing during assembly, delivery, and final deployment in the hollow vessel to provide a fast and secure closure of the access site hole. It comprises a flat base with an O-ring shape, two tabs in parallel axis to the foot core column, which protrude out from the perimeter of the O-ring, a threaded section, and recessed sections and through holes.
In some embodiments, the foot core is an integral part of the implant. It includes a hole from the bottom of the center of the O-ring section to the top of the column for guide wire access. It further includes a hole in the foot core column to hold the pin. It includes two recesses on the proximal tip of the column for engaging with the delivery system.
In some embodiments, the shapes of the two spokes in the O-ring are different. This serves the purpose of the larger rear spoke providing extra support (see, for example,
In some embodiments, the surface of a vessel lumen can be uneven and is not always uniformly smooth. The ability of the wings to form an effective seal against a vessels wall can be adversely affected if it has a very uneven topography. The rear spoke member, in some embodiments, pushes the wing against the vessel wall forcing the artery to conform to the wing. This creates a seal between the wing and the vessel surface in a variety of vessel surface topographies.
In some embodiments, the base of the O-Ring is flat, at rest, while the artery has a curvature. When the O-Ring implant is deployed into the artery, the flat foot core base adapts to the curvature of the artery and, in some embodiments, pushes the wing against the artery wall to form a contact between the flexible wing and artery inner luminal wall. This may directly enhance the effectiveness of the seal at the tamponade stage of the deployment as it does not rely on the user having to hold the device in a precise location.
In some embodiments, although the O-Ring foot core is constructed of a plastic material, its profile is thin enough to facilitate the “compression/folding” of the transverse sections and not damage itself or the flexible wing during pass through of the implant in the funnel into the loading cannula. The geometry of the foot core base allows the supporting members to fold down under the foot core as it is withdrawn through the loading funnel. The extra support member also keeps the wing in contact with the funnel internal surface during loading giving more consistent loading.
The O-ring foot core design and its variants provides, in some embodiments, support for the flexible wing portion of the implant throughout the life cycle of the implant from initial manufacturing when the implant is assembled through transportation and storage and ultimately during all stages of implant deployment into the hole in the hollow vessel for which it is intended to seal. The O-ring foot core provides, in some embodiments, structural support for the flexible wing when the device is fully assembled in its storage tray. During deployment to close a hole in a hollow vessel, the implant is loaded into a cannula through a loading funnel which reduces the cross-sectional area of the implant (O-ring and flexible wing) to make it possible to deliver the implant through an introducer catheter into a hollow vessel (such as an artery or a vein) within which there had been made an access hole to perform a minimally invasive procedure. During this delivery and deployment of the implant, in certain embodiments, the O-ring foot core supports the wing.
Uses can include closing access site holes in hollow vessels; closing access site holes in blood vessels; closing holes in arteries; closing small and large holes up to 30F in hollow vessels; closing access site holes in the abdominal post endoscopic procedures; and closing access site holes in the femoral artery, subclavian artery, ascending aorta, axillary and brachial arteries.
Although certain figures and embodiments relate to use of systems and devices for closure of a perforation associated with vascular surgery, one of ordinary skill in the art will appreciate that components of a provided device are not size dependent (i.e., are scalable) and are therefore useful for closure of any perforation in a lumen of a mammal.
Although certain figures and embodiments relate to use of systems and devices for closure of a perforation associated with vascular surgery, one of ordinary skill in the art will appreciate that components of a provided device are not size dependent (i.e., are scalable) and are therefore useful for closure of any perforation in a lumen of a mammal.
Some embodiments of the present invention are directed to a closure system, device, and method of percutaneous closure of an arteriotomy following endovascular/intra S arterial procedures.
Although the present invention has been described with reference to particular examples and exemplary embodiments, it should be understood that the foregoing description is in no manner limiting. Moreover, the features described herein may be used in any combination.
In certain embodiments, the invention is used for closing access site holes in blood vessels or arteries, for example, but not limited to, the femoral artery, subclavian artery, ascending aorta, axillary and brachial arteries.
In certain embodiments, the invention is used for closing access site holes in the abdominal post endoscopic procedures.
In certain embodiments, the invention is used for closing access site holes in hollow vessels. The size of the site holes may be up to 30 French (F) in certain embodiments.
Experimental Data
The provided technologies were tested in vitro and in vivo. For the in vitro test, the sealable member was tested on a test bench using either a flexible tube or a bovine artery to simulate the body lumen. The bovine artery has an inner diameter between 7.8 mm and 9 mm and a wall thickness between 1.4 and 1.9 mm. The flexible tube has an inner diameter of 7.1 mm and a wall thickness of 0.55 mm. In each of the flexible tube and the bovine artery, an aperture was created with a diameter of 6 and 8 mm respectively. A deployment sheath (e.g., the delivery cannula), used in the procedure, has an inner/outer diameter of 20F/24F.
The test was performed with water flowing through each of the respective bovine artery and flexible tube, under physiological conditions with a pulse of approximately 60 hertz, a systolic pressure of about 120 mm-Hg, and a diastolic pressure of about 80 mm-Hg. Ten data samples were collected for each test. The amount of water leaked within 5 minutes from the time of deployment is measured and provided in Table 4 and Table 5 below.
The test illustrates a 5× improvement of the closure device, configured with a flexible support member and a flexible sealable member (e.g., comprising the mesh layer and substrate), in reducing the amount of fluid leakage over the design employing a sealable with no mesh layer (and having a rigid core). In addition to the seal formed from the R #2 closure device having improved leakage performance, as shown in the plots of the histograms and the standard deviation values of the tables, a more consistent closure is also provided.
For the in vivo test, the sealable member was tested in animal subjects. A similar 6 mm puncture was made in a pig aorta. The deployment sheath, used in the procedure, also has an inner/outer diameter of 20F/24F. Six data samples were collected for each test using the R #1 design and the R #2 design. The total deployment time, tamponade time, time to hemostasis, and total procedure time are provided in Table 6 below.
As shown in Table 6, the R #2 design improves the total deployment time by 2.5× over the R #1 design. The total deployment time, used in the observations, includes the time for the device to be positioned and deployed in the pig aorta and for the leakage to stop.
In addition, the R #2 design improves the time to hemostasis by 9× over the R #1 design. The time to hemostasis (TTH), used in the observations, refers to the time from which a seal is created and the time for leakage to stop. Less variability in the time to hemostasis is also observed.
In addition, the R #2 design reduces the overall closure procedure time by 3.7× over the R #1 design. The activated clotting time (ACT time) was longer by over 100 seconds. The activated clotting time refers to the time for whole blood to clot upon exposure to an activator.
Although the present invention has been described with reference to particular examples and exemplary embodiments, it should be understood that the foregoing description is in no manner limiting. Moreover, the features described herein may be used in any combination.
This application is U.S. National Stage Application filed under 35 U.S.C. § 371 based on International Application No. PCT/EP2016/081183 filed Dec. 15, 2016, which claims priority to and the benefit of U.S. Provisional Application No. 62/267,644 filed Dec. 15, 2015, the entire contents of each of which are hereby incorporated by reference.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/EP2016/081183 | 12/15/2016 | WO | 00 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2017/102941 | 6/22/2017 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
321721 | Hassan | Jul 1885 | A |
2001638 | Tornsjo | May 1935 | A |
2560162 | Ferguson | Jul 1951 | A |
2778254 | Carapellotti | Jan 1957 | A |
3874388 | King et al. | Apr 1975 | A |
4299230 | Kubota | Nov 1981 | A |
4583540 | Malmin | Apr 1986 | A |
4650472 | Bates | Mar 1987 | A |
4705040 | Mueller et al. | Nov 1987 | A |
4744364 | Kensey | May 1988 | A |
4852568 | Kensey | Aug 1989 | A |
4890612 | Kensey | Jan 1990 | A |
4896668 | Popoff et al. | Jan 1990 | A |
5021059 | Kensey et al. | Jun 1991 | A |
5037433 | Wilk et al. | Aug 1991 | A |
5053046 | Janese | Oct 1991 | A |
5085661 | Moss | Feb 1992 | A |
5127412 | Cosmetto et al. | Jul 1992 | A |
5171258 | Bales et al. | Dec 1992 | A |
5192301 | Kamiya et al. | Mar 1993 | A |
5269804 | Bales et al. | Dec 1993 | A |
5282827 | Kensey et al. | Feb 1994 | A |
5320461 | Stanesic | Jun 1994 | A |
5330488 | Goldrath | Jul 1994 | A |
5336231 | Adair | Aug 1994 | A |
5342393 | Stack | Aug 1994 | A |
5350399 | Erlebacher et al. | Sep 1994 | A |
5366480 | Corriveau et al. | Nov 1994 | A |
5391182 | Chin | Feb 1995 | A |
5431639 | Shaw | Jul 1995 | A |
5462560 | Stevens | Oct 1995 | A |
5470337 | Moss | Nov 1995 | A |
5501691 | Goldrath | Mar 1996 | A |
5501700 | Hirata | Mar 1996 | A |
5507755 | Gresl et al. | Apr 1996 | A |
5527322 | Klein et al. | Jun 1996 | A |
5531759 | Kensey et al. | Jul 1996 | A |
5545178 | Kensey et al. | Aug 1996 | A |
5549633 | Evans et al. | Aug 1996 | A |
5593422 | Muijs Van de Moer et al. | Jan 1997 | A |
5601557 | Hayhurst | Feb 1997 | A |
5601571 | Moss | Feb 1997 | A |
5620461 | Muijs Van De Moer et al. | Apr 1997 | A |
5653716 | Malo et al. | Aug 1997 | A |
5662681 | Nash et al. | Sep 1997 | A |
5665096 | Yoon | Sep 1997 | A |
5676689 | Kensey et al. | Oct 1997 | A |
5690674 | Diaz | Nov 1997 | A |
5700273 | Buelna et al. | Dec 1997 | A |
5700277 | Nash et al. | Dec 1997 | A |
5707393 | Kensey et al. | Jan 1998 | A |
5722981 | Stevens | Mar 1998 | A |
5755727 | Kontos | May 1998 | A |
5782861 | Cragg et al. | Jul 1998 | A |
5797939 | Yoon | Aug 1998 | A |
5814065 | Diaz | Sep 1998 | A |
5817074 | Racz | Oct 1998 | A |
5827281 | Levin | Oct 1998 | A |
5860990 | Nobles et al. | Jan 1999 | A |
5861003 | Latson et al. | Jan 1999 | A |
5868762 | Cragg et al. | Feb 1999 | A |
5916236 | Muijs Van de Moer et al. | Jun 1999 | A |
5935147 | Kensey et al. | Aug 1999 | A |
5941899 | Granger et al. | Aug 1999 | A |
5954732 | Hart et al. | Sep 1999 | A |
5997515 | de la Torre et al. | Dec 1999 | A |
6007563 | Nash et al. | Dec 1999 | A |
6033427 | Lee | Mar 2000 | A |
6056768 | Cates et al. | May 2000 | A |
6080183 | Tsugita et al. | Jun 2000 | A |
6126675 | Shchervinsky et al. | Oct 2000 | A |
6136010 | Modesitt et al. | Oct 2000 | A |
6179863 | Kensey et al. | Jan 2001 | B1 |
6190400 | Van De Moer et al. | Feb 2001 | B1 |
6200328 | Cragg et al. | Mar 2001 | B1 |
6206895 | Levinson | Mar 2001 | B1 |
6241768 | Agarwal et al. | Jun 2001 | B1 |
6245080 | Levinson | Jun 2001 | B1 |
6296658 | Gershony et al. | Oct 2001 | B1 |
6319263 | Levinson | Nov 2001 | B1 |
6350274 | Li | Feb 2002 | B1 |
6375671 | Kobayashi et al. | Apr 2002 | B1 |
6383208 | Sancoff et al. | May 2002 | B1 |
6395015 | Borst et al. | May 2002 | B1 |
6398796 | Levinson | Jun 2002 | B2 |
6425911 | Akerfeldt et al. | Jul 2002 | B1 |
6461364 | Ginn et al. | Oct 2002 | B1 |
6485481 | Pfeiffer | Nov 2002 | B1 |
6500184 | Chan et al. | Dec 2002 | B1 |
6508828 | Akerfeldt et al. | Jan 2003 | B1 |
6520951 | Carrillo, Jr. et al. | Feb 2003 | B1 |
6596012 | Akerfeldt et al. | Jul 2003 | B2 |
6596014 | Levinson et al. | Jul 2003 | B2 |
6596915 | Satyapal et al. | Jul 2003 | B1 |
6638286 | Burbank et al. | Oct 2003 | B1 |
6669707 | Swanstrom et al. | Dec 2003 | B1 |
6669735 | Pelissier | Dec 2003 | B1 |
6702835 | Ginn | Mar 2004 | B2 |
6730112 | Levinson | May 2004 | B2 |
6764500 | Muijs Van De Moer et al. | Jul 2004 | B1 |
6770070 | Balbierz | Aug 2004 | B1 |
6779701 | Bailly et al. | Aug 2004 | B2 |
6786915 | Akerfeldt et al. | Sep 2004 | B2 |
6860895 | Akerfeldt et al. | Mar 2005 | B1 |
6890342 | Zhu et al. | May 2005 | B2 |
6932824 | Roop et al. | Aug 2005 | B1 |
6939363 | Akerfeldt | Sep 2005 | B2 |
6942674 | Belef et al. | Sep 2005 | B2 |
6949107 | McGuckin, Jr. et al. | Sep 2005 | B2 |
6949114 | Milo et al. | Sep 2005 | B2 |
6964668 | Modesitt et al. | Nov 2005 | B2 |
6969397 | Ginn | Nov 2005 | B2 |
6984219 | Ashby et al. | Jan 2006 | B2 |
6989022 | Nowakowski | Jan 2006 | B2 |
6997940 | Bonutti | Feb 2006 | B2 |
7001398 | Carley et al. | Feb 2006 | B2 |
7001400 | Modesitt et al. | Feb 2006 | B1 |
7008440 | Sing et al. | Mar 2006 | B2 |
7008441 | Zucker | Mar 2006 | B2 |
7008442 | Brightbill | Mar 2006 | B2 |
7094248 | Bachinski et al. | Aug 2006 | B2 |
7169168 | Muijs Van De Moer et al. | Jan 2007 | B2 |
7326221 | Sakamoto et al. | Feb 2008 | B2 |
7462188 | McIntosh | Dec 2008 | B2 |
7534248 | Mikkaichi et al. | May 2009 | B2 |
7569063 | Bailly et al. | Aug 2009 | B2 |
7662161 | Briganti et al. | Feb 2010 | B2 |
7678133 | Modesitt | Mar 2010 | B2 |
7753935 | Brett et al. | Jul 2010 | B2 |
7846180 | Cerier | Dec 2010 | B2 |
7918868 | Marshall et al. | Apr 2011 | B2 |
7998169 | Modesitt | Aug 2011 | B2 |
8002791 | Modesitt | Aug 2011 | B2 |
8002792 | Modesitt | Aug 2011 | B2 |
8002793 | Modesitt | Aug 2011 | B2 |
8012168 | Modesitt | Sep 2011 | B2 |
8083767 | Modesitt | Dec 2011 | B2 |
8137380 | Green et al. | Mar 2012 | B2 |
8177795 | Niese et al. | May 2012 | B2 |
8241325 | Modesitt | Aug 2012 | B2 |
8267942 | Szabo et al. | Sep 2012 | B2 |
8361092 | Asfora | Jan 2013 | B1 |
8529431 | Baker et al. | Sep 2013 | B2 |
8597324 | Briganti et al. | Dec 2013 | B2 |
8652166 | Åkerfeldt | Feb 2014 | B2 |
8821507 | Axelson, Jr. et al. | Sep 2014 | B2 |
8906050 | Brett et al. | Dec 2014 | B2 |
9060751 | Martin et al. | Jun 2015 | B2 |
9610070 | Martin | Apr 2017 | B2 |
9850013 | Grant et al. | Dec 2017 | B2 |
10206668 | McGoldrick et al. | Feb 2019 | B2 |
10314727 | Liu et al. | Jun 2019 | B2 |
10433826 | Grant et al. | Oct 2019 | B2 |
20010044631 | Akin et al. | Nov 2001 | A1 |
20020019648 | Akerfeldt et al. | Feb 2002 | A1 |
20020019649 | Sikora et al. | Feb 2002 | A1 |
20020055767 | Forde et al. | May 2002 | A1 |
20020107506 | McGuckin et al. | Aug 2002 | A1 |
20020169377 | Khairkhahan et al. | Nov 2002 | A1 |
20020177864 | Camrud | Nov 2002 | A1 |
20020198562 | Akerfeldt et al. | Dec 2002 | A1 |
20030050665 | Ginn | Mar 2003 | A1 |
20030060846 | Egnelov et al. | Mar 2003 | A1 |
20030078598 | Ginn et al. | Apr 2003 | A1 |
20030093093 | Modesitt et al. | May 2003 | A1 |
20030120305 | Jud et al. | Jun 2003 | A1 |
20030144695 | McGuckin et al. | Jul 2003 | A1 |
20030216756 | Klein et al. | Nov 2003 | A1 |
20040082906 | Tallarida et al. | Apr 2004 | A1 |
20040092964 | Modesitt et al. | May 2004 | A1 |
20040092969 | Kumar | May 2004 | A1 |
20040093025 | Egnelov | May 2004 | A1 |
20040098044 | Van de Moer et al. | May 2004 | A1 |
20040133238 | Cerier | Jul 2004 | A1 |
20040176798 | Epstein et al. | Sep 2004 | A1 |
20040243122 | Auth et al. | Dec 2004 | A1 |
20050021055 | Toubia et al. | Jan 2005 | A1 |
20050021059 | Cole et al. | Jan 2005 | A1 |
20050033326 | Briganti et al. | Feb 2005 | A1 |
20050070957 | Das | Mar 2005 | A1 |
20050143817 | Hunter et al. | Jun 2005 | A1 |
20050149065 | Modesitt | Jul 2005 | A1 |
20050181008 | Hunter et al. | Aug 2005 | A1 |
20050209613 | Roop et al. | Sep 2005 | A1 |
20050251201 | Roue et al. | Nov 2005 | A1 |
20050267520 | Modesitt | Dec 2005 | A1 |
20050273135 | Chanduszko et al. | Dec 2005 | A1 |
20050288706 | Widomski et al. | Dec 2005 | A1 |
20060100665 | Von Oepen et al. | May 2006 | A1 |
20060106418 | Seibold et al. | May 2006 | A1 |
20060142784 | Kontos | Jun 2006 | A1 |
20060142797 | Egnelov | Jun 2006 | A1 |
20060265008 | Maruyama et al. | Nov 2006 | A1 |
20060287673 | Brett et al. | Dec 2006 | A1 |
20070112385 | Conlon | May 2007 | A1 |
20070135826 | Zaver et al. | Jun 2007 | A1 |
20070179509 | Nagata et al. | Aug 2007 | A1 |
20070179527 | Eskuri et al. | Aug 2007 | A1 |
20070197858 | Goldfarb et al. | Aug 2007 | A1 |
20070255313 | Modesitt | Nov 2007 | A1 |
20070282351 | Harada et al. | Dec 2007 | A1 |
20070282373 | Ashby et al. | Dec 2007 | A1 |
20080109017 | Herweck et al. | May 2008 | A1 |
20080228204 | Hamilton et al. | Sep 2008 | A1 |
20080243148 | Mikkaichi et al. | Oct 2008 | A1 |
20080312646 | Auth et al. | Dec 2008 | A9 |
20090012521 | Axelson, Jr. et al. | Jan 2009 | A1 |
20090018574 | Martin | Jan 2009 | A1 |
20090048559 | Grathwohl | Feb 2009 | A1 |
20090088723 | Khosravi et al. | Apr 2009 | A1 |
20090112257 | Preinitz et al. | Apr 2009 | A1 |
20090143815 | Eidenschink et al. | Jun 2009 | A1 |
20090143821 | Stupak | Jun 2009 | A1 |
20090312786 | Trask et al. | Dec 2009 | A1 |
20090319017 | Berez et al. | Dec 2009 | A1 |
20100022823 | Goldfarb et al. | Jan 2010 | A1 |
20100094425 | Bentley et al. | Apr 2010 | A1 |
20100114159 | Roorda et al. | May 2010 | A1 |
20100125296 | Modesitt | May 2010 | A1 |
20100152772 | Brett et al. | Jun 2010 | A1 |
20100222796 | Brett et al. | Sep 2010 | A1 |
20100228184 | Mavani et al. | Sep 2010 | A1 |
20100292717 | Petter-Puchner et al. | Nov 2010 | A1 |
20110077667 | Singhatat et al. | Mar 2011 | A1 |
20110082495 | Ruiz | Apr 2011 | A1 |
20110087270 | Penner et al. | Apr 2011 | A1 |
20110224728 | Martin et al. | Sep 2011 | A1 |
20110270284 | Beauchamp et al. | Nov 2011 | A1 |
20120059399 | Hoke et al. | Mar 2012 | A1 |
20120089166 | Modesitt | Apr 2012 | A1 |
20120165957 | Everland et al. | Jun 2012 | A1 |
20120226308 | Martin et al. | Sep 2012 | A1 |
20120226309 | Jonsson | Sep 2012 | A1 |
20120296275 | Martin et al. | Nov 2012 | A1 |
20120302987 | Jonsson | Nov 2012 | A1 |
20130116799 | Derwin et al. | May 2013 | A1 |
20130218125 | Stopek et al. | Aug 2013 | A1 |
20130218201 | Obermiller et al. | Aug 2013 | A1 |
20130274795 | Grant | Oct 2013 | A1 |
20140018846 | Grant et al. | Jan 2014 | A1 |
20140018847 | Grant et al. | Jan 2014 | A1 |
20140058439 | White | Feb 2014 | A1 |
20140180314 | Asfora | Jun 2014 | A1 |
20140194926 | Bailly et al. | Jul 2014 | A1 |
20140200597 | Klein | Jul 2014 | A1 |
20140207183 | Shipp | Jul 2014 | A1 |
20140277113 | Stanley et al. | Sep 2014 | A1 |
20140345109 | Grant et al. | Nov 2014 | A1 |
20150045818 | Kim et al. | Feb 2015 | A1 |
20160051239 | Martin et al. | Feb 2016 | A1 |
20160166241 | McGoldrick et al. | Jun 2016 | A1 |
20170181736 | McGoldrick et al. | Jun 2017 | A1 |
20170281142 | Martin et al. | Oct 2017 | A1 |
20200138421 | Grant et al. | May 2020 | A1 |
Number | Date | Country |
---|---|---|
101400308 | Apr 2009 | CN |
104287803 | Jan 2015 | CN |
104771200 | Jul 2015 | CN |
105073064 | Nov 2015 | CN |
19711288 | Nov 2004 | DE |
102010048908 | Apr 2012 | DE |
102013101338 | Aug 2014 | DE |
0551198 | Jul 1993 | EM |
0761250 | Mar 1997 | EP |
0894475 | Feb 1999 | EP |
1 046 375 | Oct 2000 | EP |
1879505 | Jan 2008 | EP |
2260770 | Dec 2010 | EP |
2 292 147 | Mar 2011 | EP |
2 628 592 | Aug 2013 | EP |
2 777 543 | Sep 2014 | EP |
WO-1994008513 | Apr 1994 | WO |
WO-0007520 | Feb 2000 | WO |
WO-2000033744 | Jun 2000 | WO |
WO-2002102236 | Dec 2002 | WO |
WO-2004012601 | Feb 2004 | WO |
WO-2004012603 | Feb 2004 | WO |
WO-2004012627 | Feb 2004 | WO |
WO-2006117766 | Nov 2006 | WO |
WO-2007011353 | Jan 2007 | WO |
WO-2007057933 | May 2007 | WO |
WO-2007089603 | Aug 2007 | WO |
WO-2008042229 | Apr 2008 | WO |
WO-2008152617 | Dec 2008 | WO |
WO-2009070651 | Jun 2009 | WO |
WO-2009149455 | Dec 2009 | WO |
WO-2010027693 | Mar 2010 | WO |
WO-2010123821 | Oct 2010 | WO |
WO-2011080588 | Jul 2011 | WO |
WO-2012090069 | Jul 2012 | WO |
WO-2012156819 | Nov 2012 | WO |
WO-2013007534 | Jan 2013 | WO |
WO-2013128292 | Sep 2013 | WO |
WO-2013188351 | Dec 2013 | WO |
WO-2014140325 | Sep 2014 | WO |
WO-2014141209 | Sep 2014 | WO |
WO-2014149642 | Sep 2014 | WO |
WO-2016096930 | Jun 2016 | WO |
WO-2016096932 | Jun 2016 | WO |
WO-2017102941 | Jun 2017 | WO |
Entry |
---|
U.S. Appl. No. 62/092,212, filed Dec. 15, 2014, McGoldrick et al. |
U.S. Appl. No. 62/092,240, filed Dec. 15, 2014, Grant et al. |
U.S. Appl. No. 62/092,235, filed Dec. 15, 2014, Grant et al. |
Grant, et al., Hales' 1733 Haemastaticks, Anesthesiology, 112(1) (2010). |
Hales, Stephen, Statical Essays, vol. 2 (1773). |
International Search Report, PCT/EP2016/081183, 5 pages, dated Mar. 20, 2017. |
Written Opinion, PCT/EP2016/081183, 12 pages, dated Mar. 20, 2017. |
Number | Date | Country | |
---|---|---|---|
20190021710 A1 | Jan 2019 | US |
Number | Date | Country | |
---|---|---|---|
62267644 | Dec 2015 | US |